Summary
Dr. Bisht presents a randomised controlled trial comparing vernakalant against procainamide in the cardioversion of acute atrial fibrillation. The trial was performed in 12 emergency departments in Canada in patients suitable for a rhythm control strategy with acute atrial fibrillation. Discussion centred on the relevance to UK emergency departments considering the infrequent use of procainamide, description of the results in terms of absolute differences and odds ratios and discrepancy of outcomes depending upon age.
Key Learning Points
- An open label trial means that participants,clinicians and researchers are all aware of group allocation.
- Stratified randomization allows equalization of confounding factors between all arms of thetrial
- Consider the setting in which a study has been conducted and its generalizability to the setting and population where you work
- The absolute difference(or absolute risk reduction)between the two treatments is the most useful and easily understandable way of describing the difference between intervention and placebo.
- Odds ratios are less intuitive to understand that absolute risk reduction and can be used toembellishthe impact of an intervention.
Original Article Title: Vernakalant versus procainamide for rapid cardioversion of patients with acute atrial fibrillation (RAFF4): randomised clinical trial
Original Journal Reference: https://www.bmj.com/content/391/bmj-2025-085632
